Table 1.
The application of MSCs in GvHD.
| Clinical research | Source of MSCs | Injection-method | Injection dose | Type of Study | Research results | References |
|---|---|---|---|---|---|---|
| CBT combined MSCs (MSC-CBT) | BM-MSCs | Intramedullary injection | / | Phase I trial | Co-transplantation of MSCs may prevent GvHD with no inhibition of engraftment | (113) |
| CBT combined MSCs (MSC-CBT) | BM-MSCs | Intramedullary injection | 0.5 × 106/kg | Phase I trial | The safety of CBT combined with intrabone marrow injection of MSCs | (114) |
| GvHD after HSC transplantation | AT-MSCs | / | 1 × 106/kg, 3 × 106/kg | Phase I/II trial | AT-MSCs, in combination with immunosuppressive therapy, may be considered feasible and safe | (115) |
| Akt1-MSCs Ameliorates Acute Liver GVHD. | BM-MSCs | / | / | Prospective controlled study | BM-MSCs genetically modified with Akt1 have a survival advantage and an enhanced immunomodulatory function | (116) |
| Steroid-refractory GvHD after HSC transplantation | BM-MSCs | Intravenous injection | 6.81 × 106/kg (range, 0.98–29.78 × 106/kg) | Multi-center retrospective study | This therapeutic modality is safe and should be considered for steroid-refractory aGvHD | (117) |
CBT, cord blood transplantation; MSCs-CBT, CBT combined MSCs; HSC, haploid hematopoietic stem cell; AT-MSCs, adipose tissue-derived mesenchymal stromal cells; Akt1-MSCs, BM-MSCs genetically modified with AKT1; aGvHD, acute graft-versus-host disease.